S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer

Sponsor
Korean Cancer Study Group
Study ID
NCT00343668
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • S-1, irinotecan — DRUG
    S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1

Study Details

The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.

Key Dates

First listed
Jun 23, 2006
Start date
Sep 30, 2005
Status verified
Jun 2006
Primary completion
Mar 31, 2007
Completion
Jul 31, 2008

Study Design

Enrollment
44 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

response rate [ Time Frame: best response ]

Central Contacts

Find similar trials

Nationwide
Gastric cancer trialsOncology trialsGI oncology trials

Related Studies